Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-dose, single-period, parallel group designed study to determine
the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of CTP-543
and its major metabolites following administration of a single 12 mg oral dose of CTP-543.